Dent Neurologic

DENTNeuro_White

Alzheimer’s Study

IGC Pharma

IGC PHARMA (Alzheimer’s Disease with Agitation) This is a trial of the safety and efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease. Inclusion Criteria: 60 years of age and above Diagnosis of probable Alzheimer’s Disease Clinically significant agitation, must have a caregiver who can comply with required procedures What to […]

IGC Pharma Read More »

ACADIA RADIANT

ACADIA RADIANT (Alzheimer’s Disease Psychosis) In this study, researchers will evaluate ACP-204 in patients with Alzheimer’s Disease Psychosis. Inclusion Criteria:  50 years to 95  years of age Meets clinical criteria for possible or probable Alzheimer’s Disease Psychotic symptoms (hallucinations or delusions) for at least 2 months Availability of a designated study partner/caregiver What to Expect

ACADIA RADIANT Read More »

SUVEN CTP3S1502HT6

SUVEN CTP3S1502HT6 (Alzheimer’s Disease with Agitation) This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer’s type. Inclusion Criteria:  50 years to 9o years Alzheimer’s Dementia (full criteria in link below) What to Expect Study

SUVEN CTP3S1502HT6 Read More »

BIOGEN CELIA

BIOGEN CELIA In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or mild dementia due to AD. The main question researchers are trying to answer is if BIIB080 can slow the worsening of AD more than placebo. It will focus on

BIOGEN CELIA Read More »

ADCS BENFO-TEAM

ADCS BENFO-TEAM The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer’s disease. Inclusion Criteria:  50 years to 89 years Mild Cognitive Impairment or Alzheimer’s Disease Availability of a designated study

ADCS BENFO-TEAM Read More »

Scroll to Top